"Tesa 30mg" refers to tesamorelin supplied at a 30mg fill — most often the pre-filled 30mg/3ml pen rather than a lyophilised vial. The distinction matters more than it sounds, because the two formats have different stability profiles and are priced in units that do not compare at a glance.
Proxiva Formulation DeskBlends, fill weights and multi-component products
Key takeaways
- Tesamorelin is a synthetic analogue of growth hormone releasing hormone — a 44-residue peptide with a modification that resists rapid enzymatic breakdown.
- "30mg" almost always means the pre-filled pen at 30mg/3ml, which arrives already in solution.
- The lyophilised vial and the pen are different products: the vial's stability clock starts when you reconstitute, the pen's started at manufacture.
- It is a GHRH analogue, which puts it in the same mechanistic class as CJC-1295 no-DAC and distinct from ghrelin-receptor agonists like Ipamorelin.
- At 44 residues it is a long peptide by synthesis standards, which is why it costs more per milligram than short peptides.
What "tesa 30mg" actually refers to
Tesamorelin is a synthetic analogue of growth hormone releasing hormone. The native hormone is 44 amino acids long, and tesamorelin retains that full length with a modification at the N-terminus — a trans-3-hexenoyl group attached to the first residue.
That modification is the entire point of the molecule. Native GHRH is degraded very rapidly in circulation, primarily by dipeptidyl peptidase-4, which cleaves the first two residues. Blocking access to that cleavage site extends how long the peptide survives, which is what makes the analogue usable where the native hormone is not.
The "30mg" in the search term is a fill weight, and in practice it points at a specific product: the pre-filled 30mg/3ml pen. The lyophilised material is listed separately as Tesamorelin, and there is also a full kit for researchers buying at volume.
If you are comparing prices across suppliers, establish which of those three you are looking at before comparing anything. They are not interchangeable listings.
Pen versus vial at this fill
Two formats carrying the same compound, decided by what the protocol needs rather than by which is better.
| Consideration | Vial | 30mg/3ml pen |
|---|---|---|
| Arrives as | Dry cake | Solution |
| Concentration | Set by the operator | 10mg/ml, fixed |
| Clock starts | On reconstitution | At the fill, date usually undisclosed |
| Draw variance | Depends on the syringe and the hand | Mechanical, repeatable |
| Holds well long-term | Yes | No — solution degrades |
| Reconstitution risk | Present | Removed |
The concentration figure is arithmetic: 30mg across 3ml gives 10mg/ml, and no amount of handling changes it.
Chain length is the reason the storage row carries weight here. Forty-four residues present considerably more hydrolysis- and oxidation-susceptible sites than a five-residue peptide does, so time spent dissolved costs more. A pen has been dissolved since manufacture. Ask when — and treat a supplier's willingness to say as part of the answer. Format trade-offs generally are in pens versus vials.
Work out what you are paying per milligram
Do this before comparing anything. Four steps.
- Read the fill. A pen states 30mg/3ml. A vial states its own weight. These are not the same unit.
- Divide. Price over milligrams. That is your baseline number.
- Ask whether the figure is net. Stated weight usually includes water and counterion. HPLC purity does not measure either. Get the net figure or treat your baseline as optimistic.
- Add transit. Heat exposure degrades peptides and nothing recovers it. A cheaper vial that sat warm for a week is not cheaper.
Expect this compound to price high, and know why. Synthesis adds one residue at a time. Yield compounds across every step. A five-residue peptide finishes near 95% crude. Forty-four residues finishes near 64% — before purification throws more away.
| Peptide | Residues | Crude yield at 99%/step |
|---|---|---|
| Ipamorelin | 5 | ~95% |
| Semax | 7 | ~93% |
| BPC-157 | 15 | ~86% |
| Tesamorelin | 44 | ~64% |
So a supplier selling 44 residues at high purity is discarding a lot. Treat an unusually cheap listing as a question, not a win. Open the chromatogram and look at what sits beside the main peak.
Place it correctly before you buy
The compound sits within a lineage that is worth reconstructing, because the position it occupies explains both what it is for and why several apparently similar products exist alongside it.
Work on the hypothalamic releasing factors proceeded through the middle decades of the twentieth century, and by the time the growth hormone releasing hormone had been characterised, the pattern common to that whole family of molecules was already familiar: a short peptide signal, produced in one structure, acting upon another, and cleared from circulation with considerable speed. That final property, which serves the organism well in a regulatory system requiring precise timing, presented an obstacle to anyone wishing to administer such a signal deliberately.
Several groups addressed the obstacle in the decades that followed, and the approaches they took were different enough that the resulting compounds are genuinely distinct rather than variations upon a single theme. One approach lengthened the molecule's persistence by shielding the position at which enzymes cleave it, which is the strategy this compound represents. Another engaged the same pituitary output through an entirely separate receptor, which is the route taken by the ghrelin-receptor secretagogues, Ipamorelin among them.
Understanding that divergence is what allows the catalogue to be read correctly, since compounds arriving from the two traditions are frequently listed side by side without any indication that they solve different problems, and a purchase made without regard to the distinction is a purchase made without regard to what the material was designed to do.
CJC-1295 belongs to the first tradition and engages the same receptor as the compound discussed here, while the combined CJC-1295 and Ipamorelin preparation exists precisely because the two traditions are complementary rather than competing, a fact that was established empirically long after both molecules had been developed independently.
What the modification is for
The molecule at issue here is not the hypothalamic signal itself but a deliberately altered version of it, and the alteration has a purpose that repays understanding; the native releasing hormone is, in its unmodified state, a rather fragile thing, cleared from circulation quickly enough that its usefulness as an administered agent was limited from the outset.
The problem was recognised early. Peptides of this kind are dismantled by enzymes that recognise particular positions along the chain, and the native sequence presents such a position near its beginning; anything that could obstruct that recognition, without simultaneously destroying the molecule's ability to engage its receptor, would extend the window in which the compound remained intact.
The solution adopted was an addition at one end of the chain — a modification that shields the vulnerable position from the enzymes that would otherwise cleave it, while leaving the portion responsible for receptor engagement substantially undisturbed. It is a small change in structural terms and a considerable one in practical terms, and it belongs to a broader family of stabilising strategies developed across this period for much the same reason.
This history explains something that puzzles readers encountering the compound for the first time: why a modified analogue should exist at all when the natural signal is well characterised and could in principle be synthesised directly. The answer is that the natural signal was synthesised, was administered, and did not persist long enough to be useful; the modification is the response to that finding rather than an attempt to improve on nature in any grander sense.
It also explains why comparisons with other compounds acting on the same axis — CJC-1295 among them, which addresses the same fragility by a different route — turn so often on duration rather than on mechanism. The mechanism was never the difficulty. Persistence was, and the various analogues in circulation represent competing answers to that single question.
Acceptance procedure on arrival
Work through these in order. Each step is cheaper than the one after it, so a failure caught early saves the most.
Step 1 — match the lot
Read the number printed on the pen or vial. Read the number on the certificate. If they differ, stop — the document describes other material and nothing else on it applies to what you are holding.
Step 2 — confirm the mass figure exists
Purity alone will not distinguish a full 44-residue chain from a shortened one. Locate the mass-spectrometry result and check it against the theoretical value for the complete modified sequence, including the N-terminal group. Absent that figure, treat identity as unestablished.
Step 3 — open the chromatogram
Look at the region immediately around the main peak. Long syntheses accumulate chains short by a residue, and those elute nearby. A cluster of peaks tight against the principal one means purification left them in. A single peak with clean shoulders means it did not. This distinction does not appear in the reported percentage.
Step 4 — check who tested it
The laboratory should be named, and it should not be the facility that performed the synthesis. Self-certification is not disqualifying on its own, but it should lower the weight you place on the numbers.
Step 5 — for a pen, ask which lot was tested
Pen documentation commonly covers the bulk peptide rather than the filled unit. Those are different questions. Request the certificate for the fill.
Step 6 — inspect and store
White to off-white cake for the lyophilised form; discolouration warrants a query before use. Then straight to cold storage — transit heat is cumulative and nothing recovers it.
Field-level detail on each certificate entry is in how to read a certificate of analysis.
Handling
Ordinary discipline for the vial; less within your control for the pen.
- Sealed lyophilised vial: cold, dry, protected from light
- Reach room temperature before opening so moisture does not condense onto cold powder
- Reconstitute with bacteriostatic water for any vial punctured more than once
- Run diluent down the vial wall, never onto the powder cake
- Swirl to dissolve; never shake
- Refrigerate afterwards, label with date and volume, never re-freeze
For the pen, storage is refrigeration and light protection — there is no reconstitution step to get right, which is the format's main advantage. The reasoning behind each rule is in reconstituting research peptides and storage and stability.
Supplier assessment generally, including why vendor longevity stopped being a reliable signal in 2026, is covered in choosing a research peptide supplier.
Frequently asked questions
What does "tesa 30mg" mean?
A tesamorelin product at a 30mg fill — in practice usually the pre-filled 30mg/3ml pen, which works out to 10mg/ml, rather than a lyophilised vial.
What is tesamorelin?
A synthetic analogue of growth hormone releasing hormone. It retains the native 44-residue sequence with a trans-3-hexenoyl group at the N-terminus, which blocks the cleavage site that degrades the native hormone rapidly.
Why is it more expensive than other peptides?
Chain length. Synthesis yield compounds across every coupling step, so a 44-residue peptide finishes at roughly 64% crude yield against ~95% for a 5-residue one — before purification losses.
Is it the same as CJC-1295?
No. Both are GHRH analogues, but tesamorelin is the full 44-residue sequence with an N-terminal modification while CJC-1295 no-DAC is a shorter modified fragment. Their masses differ substantially.
Should I buy the pen or the vial?
The vial for long storage and adjustable concentration; the pen for measurement repeatability and to skip reconstitution. At this chain length, extended time in solution matters more than it would for a short peptide.
What should the certificate show for a pen?
Everything required for a vial, plus a certificate corresponding to the filled lot rather than only the bulk synthesis lot. A certificate for the powder before filling says nothing about the filling process.
Related research compounds
- 5-Amino-1MQ – 10mg — $69.00
- Selank + Semax Full Kit (10 Vials) — 20% Off — $720
- KPV Full Kit (10 Vials) — 20% Off — $200
- AOD 9604 – 5mg — $81.00
- GLP2 T Full Kit (10 Vials) — 20% Off — $280
- GLP2 T — $70
- GLP3 - R Pen 60mg/3ml — $450
- GLP1 S Full Kit (10 Vials) — 20% Off — $240
- Selank Full Kit (10 Vials) — 20% Off — $240
- Melanotan II (MT-II) — $50
- Melanotan II Full Kit (10 Vials) — 20% Off — $200
Further reading
Research use only. All products referenced on this page are sold strictly for laboratory and research purposes. They are not drugs, foods, cosmetics, or medical devices, and they are not intended to diagnose, treat, cure, or prevent any disease. They are not for human or veterinary consumption. Handling should be performed only by qualified individuals in an appropriate laboratory setting.